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Abstract
Stroke remains a major public health issue and the second leading cause of 
death worldwide. The Hippocratic Corpus used the word apoplexy to describe a 
person collapsing while retaining pulse and respiration. This is believed to be the 
first written description of stroke. The theories of what caused stroke evolved over 
the years. When autopsies were performed stroke was attributed to emboli and 
thrombi formation. Carotid endarterectomies (CEA) were then performed for 
the treatment of stroke. Originally CEA were seen with skepticism but the North 
American Symptomatic Carotid Endarterectomy trial (NASCET) and the European 
Carotid Surgery trial (ECS) helped restore their efficacy in the management of 
ischemic stroke. A milestone in the management of ischemic stroke was the use of 
intravenous tissue plasminogen activator (tPA). Secondary to the limitations of the 
use of tPA other avenues were sought which included intraarterial recombinant 
prourokinase and mechanical thrombectomy. The field of mechanical thrombec-
tomy continues to be rapidly changing and evolving. Various randomized controlled 
trials and meta-analysis have been conducted in order to evaluate who will benefit 
from mechanical thrombectomies, the timing, the best device to use and the role of 
combining this intervention with the administration of intravenous tPA.
Keywords: Ischemic stroke, history of stroke, carotid endarterectomy, intravenous 
tissue plasminogen activator, endovascular mechanical thrombectomy
1. Introduction
The World Health Organization in 1980 defined stroke as “the rapidly developed 
clinical signs of focal (or global) disturbance of cerebral function, with symptoms 
lasting 24 hours or longer or leading to death, with no apparent cause other than of 
vascular origin” [1]. In 2013, the American Stroke Association for the 21st century 
came up with a new broader definition of stroke [2]. The new definition of stroke 
includes “brain, spinal cord, or retinal cell death attributable to ischemia, based 
on 1. pathological, imaging, or other objective evidence of cerebral, spinal cord, or 
retinal focal ischemic injury in a defined vascular distribution; or 2. clinical evi-
dence of cerebral, spinal cord, or retinal focal ischemic injury based on symptoms 
persisting ≥24 hours or until death, and other etiologies excluded” [2]. Stroke is a 
major cause of morbidity and it remains the second leading cause of death world-
wide after ischemic heart disease [3, 4]. Stroke is also the third most common cause 
of disability with significant increase in stroke burden in the world and especially 
in developing countries [5]. On average in the United States (U.S.) someone has a 
stroke every 40 seconds [6].
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Stroke is divided into ischemic and hemorrhagic stroke. Hemorrhagic stroke is 
further divided into intracerebral and subarachnoid hemorrhage. Approximately 
85% of all strokes are ischemic with the remaining 15% being hemorrhagic [7]. We 
have currently moved away from using terms such as “cerebrovascular accident” 
and “reversible ischemic neurologic deficit” [7].
Transient ischemic attacks (TIA) also known as “warning strokes” are defined 
by the American Heart Association and American Stroke association as “brief 
episodes of neurological dysfunction resulting from focal cerebral ischemia not 
associated with permanent cerebral infarction” [8]. Although it is difficult to count 
the exact numbers of patients suffering from TIAs, in the U.S. this number has been 
estimated to be 200,000–500,000 per year [8].
Ischemic stroke is the result of a blockade of the arteries that supply the brain. 
The most common criteria used for classifying the causes of ischemic stroke are the 
Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria [9]. The TOAST 
criteria group the causes for ischemic stroke into five main groups which include:  
1) large-artery atherosclerosis, 2) cardioembolic, 3) small-vessel occlusion, 4) 
stroke of other determined etiology and 5) stroke of undetermined etiology [9].
Hemorrhagic stroke results from the rupture of a blood vessel resulting in blood 
outside the vessel in the brain parenchyma. Intracerebral hemorrhage has an annual 
incidence of 10–30 per 100,000 population and there has been an 18% increase in 
intracerebral hemorrhage in the last ten years [10]. Subarachnoid hemorrhage is 
the presence of blood in the subarachnoid space, the space between the arachnoid 
mater and the pia mater. Common causes of subarachnoid hemorrhage include 
trauma, rupture of an intracranial aneurysm and perimesencephalic hemorrhage 
[11]. The overall global incidence of aneurysmal subarachnoid hemorrhage is 7.9 per 
100,000 people per year [12]. Rupture of a cerebral aneurysm resulting in sub-
arachnoid hemorrhage remains a neurosurgical emergency. The mortality rate for 
patients hospitalized with non-traumatic subarachnoid hemorrhage can be higher 
than 25% [13].
Risk factors of stroke have been well established some of which are hypertension, 
hyperlipidemia, diabetes and smoking [14]. Prevention of stroke can be achieved by 
managing the above risk factors. Prevention of stroke is key as survivors of stroke often 
face poor functional outcome as well as cognitive and physiological impairment [15].
The National Institutes of Health Stroke Scale (NIHSS) is a scale used by 
medical personnel to determine the severity of the neurological deficit following 
a stroke [16]. The scale ranges from 0 to 42 with higher scores reflecting a worse 
neurological impairment [16]. The NIHSS can also be used after treatment to assess 
any improvement in clinical symptoms. The NIHSS is probably the most widely 
used stroke scale. However due to some limitations efforts are made to improve and 
modify it [17]. Another widely used scale to predict functional outcome following 
a stroke is the modified Ranking Scale (mRS) [18]. The mRS is a categorical scale 
ranging from 0 to 6 with score 0 referring to a fully independent patient and score 6 
referring to someone being dead [18].
The key in managing a patient who is experiencing a stroke is early recognition of 
symptoms. Any patient who is suspected of having a stroke should undergo emergent 
computed tomography of the brain in order to determine whether the stroke is isch-
emic or hemorrhagic in nature. If hemorrhagic stroke is excluded, ischemic stroke is 
suspected and if there are no contraindications intravenous tissue plasminogen (tPA) 
activator should be administered. Computed tomography perfusion (CTP) is neces-
sary to identify the salvageable brain region. Computed cerebral angiography (CTA) 
should also be performed to look for any large vessel occlusion. If a proximal large 
vessel occlusion in the anterior circulation is identified patients who meet the criteria 
can undergo endovascular mechanical thrombectomy to relieve the obstruction.
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Following mechanical thrombectomy the modified Thrombolysis in Cerebral 
Infarction (mTICI) grade is used to determine the percent of arterial revascular-
ization. Over the years the scale has been modified. The original scale had scores 
ranging from 0 to 4 [19]. The scores on the most recent scale range from 0 to 3 with 
score 2 being divided into a, b and c [20]. mTICI 0 refers to no perfusion or antero-
grade flow beyond the site of occlusion [20]. mTICI 1 refers to penetration but no 
perfusion [20]. mTICI 2a refers to some perfusion with distal branch filling of less 
than 50% of territory visualized [20]. mTICI 2b refers to substantial perfusion with 
distal branch filling of more than equal to 50% of territory visualized [20]. mTICI 
2c refers to near complete perfusion except for slow flow in a few distal cortical 
vessels, or presence of small distal cortical emboli [20]. mTICI 3 refers to complete 
perfusion with normal filling of distal branches [20].
Stroke is a health condition that neurosurgeons deal with on an everyday basis. 
Over the years the management of ischemic stroke is a field that has been rapidly 
evolving and advancing. The focus of this book chapter will be to discuss the 
history that has led to the current techniques used by neurosurgeons for treating 
 ischemic stroke.
2. Early understanding of stroke
The word “apoplexy” was first documented in the Hippocratic Corpus and refers 
to a person collapsing while retaining pulse and respiration [21]. In Greek language 
the word αποπληξία (apoplixia) means to be struck with violence. The following 
extract from the Hippocratic writings gives a description of apoplexy: “The healthy 
subject is taken with a sudden pain; he immediately loses his speech and rattles 
in his throat. His mouth gapes and if one calls him or stirs him he only groans but 
understands nothing. He urinates copiously without being aware of it. If fever does 
not supervene, he succumbs in seven days, but if it does he usually recovers.” [22]. 
In the Greco-Roman period apoplexy was a term used to describe strokes, epilepsy 
and migraines [21, 23]. The four humours (blood, phlegm, yellow bile and black 
bile) were first mentioned in the Hippocratic treatise called The Nature of Man, 
and it was actually the work of Polybus, Hippocrates’ student [24]. According to 
Hippocrates, apoplexy was secondary to heating of the head blood vessels that 
brought phlegm or caused the flow of black bile to the head [22]. Aretaeus was the 
first to document the concept that apoplexy to one side of the brain results to the 
contralateral paralysis of the body [25]. Galen claimed that stroke was the result of 
humors imbalance resulting in blocking the transmission of the animal spirit [26]. 
Specifically, Galen believed that blood accumulated in the brain whereas phlegm 
and black bile accumulated in the cerebral ventricles [26].
During the Medieval era the concepts around apoplexy remained grossly 
unchanged [21]. The ideas of apoplexy in the Medieval era remained influenced by 
ideas from Greco-Roman works [21].
More information into the cause of apoplexy was obtained during the 
Renaissance era, between the 14th and 17th century [21]. During the Renaissance 
era autopsies were permitted and the ancient works were translated in this way 
expanding the knowledge of apoplexy [21]. In 1599, the Oxford English Dictionary 
gave a synonym for the “stroke of the palsy” as the “stroke of God’s hands” [27].
From the 17th century and onwards the various conditions that made up the 
term apoplexy started to be individually explored [21]. In 1658, Johan Jakob Wepfer 
published “Historiae apoplecticorum” which was the first time that apoplexy was 
related to intracerebral hemorrhage [28]. Wepfer performed an autopsy on a 
patient who suffered from “apoplexy” and found that the brain and the ventricles 
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were filled with blood and no signs of external trauma were evident [28]. In 1689, 
William Cole was the first to use the term stroke to refer to apoplexy [21]. Others 
such as Morgagni (1761), Biumi (1765), Blackall (1814), Rochoux (1814) and Rostan 
(1819) shed light into diseases ranging from unruptured to ruptured aneurysms, as 
well as the difference between ischemic and hemorrhagic stroke [21].
3. The development of carotid endarterectomy
In 1852, Rudloph Virchow played an important role in shaping our understand-
ing of stroke as he was the first to identify that stroke was the result of an embolism 
and/or thrombus [21, 29]. In fact Virchow was the first to use the term “thrombosis” 
and “embolus” that can lead to decrease blood flow in distal vessels and can result in 
stroke [30].
Approximately 8% of all ischemic strokes are due to extracranial internal 
carotid artery stenosis [31]. Chiari in 1906 and Hunt in 1914 performed autopsies in 
patients who had suffered from cerebral infarction and noted that lesions in the cer-
vical carotid artery could be the culprit for the stroke [32]. Fisher in 1951, published 
case reports that showed that the cause of cerebral infarction was secondary to 
occlusion of internal carotid artery [32]. The introduction of cerebral angiography 
in 1927 by Moniz played a crucial role in the understanding of carotid artery disease 
and the subsequent development of carotid endarterectomy (CEA) [33]. The first 
carotid artery reconstruction was completed in 1951 in Buenos Aires and it was the 
result of the combined work of Fisher, Murphy, Carrea and Mollins [34]. In 1953, 
Debakey successfully completed the first CEA surgery for a patient with cerebro-
vascular insufficiency [35]. However, Debakey did not publish this case report until 
1975 [36]. In the meanwhile, in 1956 Cooley was the first to publish a case report 
on a patient undergoing a successful CEA [37]. This was also the first report of the 
application of a temporary shunt during a CEA [37].
In 1969, the Joint Study of Extracranial Arterial Occlusion was published that 
showed that in 2,400 operations performed between 1961 and 1968 there was 
a 4.5% surgical mortality [38]. The indications for CEA remained unclear and 
given the surgical risk associated with the surgery, it took years before it became 
the standard of care [39]. In 1991, The North American Symptomatic Carotid 
Endarterectomy trial (NASCET) and the European Carotid Surgery (ECS) trial 
proved that patients with symptomatic carotid stenosis of 70–99% who underwent 
CEA had better outcomes when compared to patients who were treated medi-
cally [40, 41]. Specifically, the NASCET study showed that there was an absolute 
risk reduction of 17 ± 3.5 percent (P < 0.001) of having any ipsilateral stroke at 
two years and an absolute risk reduction of 10.6 ± 2.6 percent (P < 0.001) for a 
major or fatal ipsilateral stoke when comparing patients who underwent CEA 
versus those who underwent medical management [42]. The ECS trial showed that 
patients with carotid artery stenosis of 70–99% (P < 0.0001) had a six fold reduc-
tion in their risk of experiencing stroke during the next three years if they under-
went surgical treatment versus medical management [43].
In addition, in 1995 the Asymptomatic Carotid Artery Stenosis (ACAS) trial 
showed that patient with asymptomatic carotid artery stenosis of 60% or greater 
benefited from CEA [44]. In this study there was a 53% risk reduction of having a 
stroke in patients treated surgically versus those treated medically [44].
Subsequently there was also interest as to whether carotid artery stenting (CAS) 
could replace CEAs. In 2010, a randomized controlled trial showed that CAS was 
associated with a significant higher periprocedural risk of stroke, whereas CEA was 
associated with a higher risk of myocardial infarction [45]. This study also showed 
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that in the four year follow up there was no significant difference of further strokes 
between the two groups [45].
4. Intravenous tissue plasminogen activator
A milestone in the management of ischemic stroke occurred in 1995 when 
the National Institute of Neurological Disorders and stroke rt-PA Stroke Study 
(NINDS) showed that administering intravenous recombinant tissue plasmino-
gen activator (tPA) within 3 hours of symptoms onset had favorable outcomes in 
stroke management [46]. Intravenous tPA is a thrombolytic agent used to break 
down a clot [47]. In particular, it converts the inactive plasminogen into plas-
min a proteolytic enzyme that breaks down fibrin [47]. The NINDS study was 
a randomized, double-blind trial with patients either randomized to receiving 
intravenous tPA or placebo, within 3 hours of the onset of symptoms [46]. The 
results of the study showed that neurological improvement was similar between 
the two groups 24 hours after treatment and better in the group that received 
intravenous tPA at three months [46]. The major adverse effect in the treatment 
group was symptomatic intracerebral hemorrhage within 36 hours after treat-
ment that occurred in 6.4% of the treatment group versus 0.6% of the placebo 
group (P < 0.001) [46].
The European Cooperative Acute Stroke Study (ECASS) I published in 1995 was 
a randomized controlled study that divided subjects into two groups those receiv-
ing 1.1 mg per kg of body weight of intravenous tPA or placebo [48]. Patients were 
included in the study if they presented within 6 hours from onset of symptoms and 
had moderate to severe neurological deficit [48]. Patients receiving intravenous tPA 
had better mRS at 90 days and better neurological recovery in comparison to the 
placebo group [48]. The incidence of intracerebral hemorrhage and mortality rate 
was similar between the groups [48]. However, the group receiving intravenous tPA 
had a higher incidence of large intracerebral hemorrhage [48].
Other randomized controlled studies including the ECASS II in 1998 and the 
Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke 
(ATLANTIS) B in 1999 urged against the use of intravenous tPA beyond 3 hours 
in management of ischemic stroke [49, 50]. This conclusion was based on the high 
incidence of intracerebral hemorrhage that was observed in those who received 
intravenous tPA [49, 50].
In 2008, ECASS III study, a randomized controlled study, showed that admin-
istration of intravenous tPA to patients with ischemic stroke up to 4.5 hours after 
the onset of stroke symptoms was beneficial [51]. Patients were randomly assigned 
to either receive intravenous tPA or placebo and the median time for administra-
tion of the medication was 3 hours and 59 minutes [51]. The study showed that the 
group that received tPA had better outcomes than the placebo group (52.4% vs. 
45.2%, confidence interval (CI), 1.02 to 1.76; P = 0.04) [51]. Both incidences of any 
intracerebral hemorrhage and symptomatic intracerebral hemorrhage were higher 
in the treatment group versus the placebo group with results being 27% vs. 17.6%, 
P = 0.001 and 2.4% vs. 0.2%, P = 0.008 respectively [51]. Mortality and other seri-
ous adverse events were similar between the groups [51].
Intracerebral hemorrhage following intravenous tPA remains a concern that 
can lead to devastating results. To decrease the risk of intracerebral hemorrhage 
following intravenous tPA, the American Heart Association and American Stroke 
Association issued guidelines with strict criteria for which patients are eligible for 
receiving intravenous tPA [52]. Other limitations to consider is that larger and more 
proximally located thrombi might not respond to intravenous tPA [53]. It has been 
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reported that restoration of blood flow in large vessel occlusion after intravenous 
tPA ranges between 10 and 30% depending on the large vessel that is occluded [53].
Given the limitations of intravenous tPA other avenues for management of 
ischemic stroke were needed. The Prourokinase (Prolyse) in Acute Cerebral 
Thromboembolism (PROACT II) study, a randomized controlled study aimed to 
determine the effects of administrating intraarterial recombinant prourokinase 
(r-proUK) compared to heparin within 6 hours of onset of symptoms [54]. The 
PROACT II study showed an increase in recanalization rate and improvement in 
modified Rankin score in patients treated with r-proUK versus those who were 
treated with heparin alone [54]. The major limitation of r-proUK was an increase 
in intracerebral hemorrhage 24 hours after administration that was associated with 
neurological deterioration (10% in treatment group versus 2% in control group, 
P < 0.06) [54].
Another medication that has been considered for the management of acute 
ischemic stroke is tirofiban [55]. Tirofiban is a glycoprotein IIb/IIIa platelet recep-
tor antagonist [55]. The Safety of Tirofiban in acute Ischemic Stroke (SaTIS) trial 
aimed to determine whether tirofiban could be used for the treatment of acute 
ischemic stroke [55]. SaTIS was a prospective, open-labeled treatment, blinded 
outcome reading multicenter trial [55]. Patients that were included in the study had 
an NIHSS between 4 and 18 and received either intravenous tirofiban or placebo 
up to 48 hours from onset of symptoms [55]. There was no difference between the 
two groups in terms of intracerebral hemorrhage or neurological outcome up to 
five months of treatment [55]. Five months following intervention mortality was 
lower in the treatment group [55].
5. Endovascular Mechanical Thrombectomy
In 2005, the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial 
revolutionized the way ischemic strokes are managed [56]. This was the first study 
that showed how endovascular embolectomy using a first generation device can 
improve outcomes of ischemic stroke [56]. The MERCI trial used the embolectomy 
device (Merci Retriever) for patients who presented within 8 hours of onset of 
stroke and were otherwise ineligible for intravenous tPA administration [56]. The 
study showed that recanalization was achieved in 48% of patients who underwent 
embolectomy and the risk of intracranial hemorrhage was significantly lower, only 
7.8%, in comparison to 10% in the PROACT II study [56]. In 2008, after the devel-
opment of the Merci Retriever the Penumbra System was developed. The Penumbra 
device is a second generation thrombectomy device that is inserted all the way 
through the clot followed by application of mechanical aspiration with the use of 
a suction pump [39]. By using the Penumbra System partial to normal reperfusion 
was achieved in 81.6% of patients, a percentage higher than that achieved by using 
the Merci Retriever [56, 57]. Intracranial hemorrhage was observed in 28% of 
patients on post procedural 24 hour CT scan however only 11.2% were symptomatic 
[57]. Despite the increase in intracranial hemorrhage observed with the Penumbra 
device in comparison to the Merci Retriever the 90-day mRS of less than or equal 2 
was similar between the two groups, with 25% for the Penumbra system and 27.7% 
for the Merci Retriever [56, 57]. Shortly thereafter stent retrievers were developed 
for the use as thrombectomy devices.
In 2012, a third generation mechanical thrombectomy device was introduced. 
The Solitaire Flow Restoration device versus the Merci Retriever in patients with 
acute ischemic stroke was studied [58]. The SWIFT study was a randomized, 
parallel-group, non-inferiority trial that showed that Solitaire Flow Restoration 
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device is significantly better than the Merci retriever device [58]. In particular, 
patients treated with the Solitaire Flow Restoration device had a rate of recanaliza-
tion of 61% in comparison to 24% in those treated with the Merci Retriever device 
[58]. With the use of the Solitaire flow restoration device the rate of symptomatic 
intracranial hemorrhage was decreased and the overall neurological outcomes were 
better [58].
Another area of interest was whether devices that combined direct aspiration 
with thrombectomy would be beneficial in the management of ischemic stroke. 
The MAX reperfusion catheters as well as a direct aspiration first pass technique 
(ADAPT) enabled direct aspiration with thrombectomy [53]. In 2018, a randomized 
controlled study aimed to determine whether there was a difference in ischemic 
stroke outcomes when the novel 3-dimensional (3-D) stent retriever was used in 
conjugation with an aspiration-based mechanical thrombectomy device (Penumbra 
System; Penumbra) versus the aspiration-based thrombectomy alone [59]. The 
results of the study showed that 87.2% in the 3-D stent retriever with aspiration 
group versus 82.3% in the aspiration based thrombectomy alone group had a 
mTICI of 2–3 [59]. The 90-day mRS score of 0 to 2, device-related serious adverse 
events and procedure-related serious adverse events were similar between the two 
groups [59].
The next step in the management of acute ischemic stroke was to determine 
whether endovascular thrombectomy was superior to standard medical care alone 
[60]. There were five key randomized control studies that aimed to answer this 
question: MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, and EXTEND IA 
[61–65].
The MR CLEAN trial aimed to determine whether patients who presented 
within 6 hours after onset of ischemic symptoms and proximal intracranial occlu-
sion of the anterior circulation would benefit from mechanical thrombectomy [61]. 
In particular, all patients in the study received intravenous tPA and were subse-
quently randomized to receive either intraarterial treatment or not [61]. The study 
showed that there was improvement in functional independence in the treatment 
group but no changes in mortality or the occurrence of symptomatic intracerebral 
hemorrhage between the two groups [61].
The ESCAPE study assessed whether patients who presented within 12 hours 
of onset of symptoms would benefit from mechanical thrombectomy [62]. The 
patients included in the study had a proximal vessel occlusion in the anterior 
circulation and they all received intravenous tPA [62]. The experimental group 
also received mechanical thrombectomy [62]. The results of the study showed that 
patients who received mechanical thrombectomy had substantial increase of func-
tional independence (53% in the treatment group versus 29.3% in the control group; 
P < 0.001), decreased mortality in the intervention group and similar intracerebral 
hemorrhage rates [62].
The REVASCAT study examined whether there is a difference in outcome in 
patients when treated with a combination therapy of both intravenous tPA (if 
eligible) and mechanical thrombectomy than those treated with medical therapy 
alone [63]. The patients who were included in the study had to present within 
8 hours of onset of symptoms and had to have a proximal anterior circulation occlu-
sion [63]. Solitaire stent retriever was the device used for the thrombectomy group 
[63]. The results of the study showed that functional independence was increased 
in the experimental group, with 43.7% having functional independence (mRS score 
of 0–2) in 90 days versus 28.2% in the control group [63]. The rates of intracerebral 
hemorrhage remained the same in both groups [63].
The SWIFT PRIME study aimed to determine whether patients treated with 
both intravenous tPA and Solitaire Revascularization Device within 6 hours of 
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symptoms onset had better outcome than those who were treated with intravenous 
tPA alone [64]. The results of the study showed that there was a greater proportion 
of patients in the experimental group that were functional independent at 90 days 
in comparison to the control group [64]. Secondary outcomes such as functional 
independence at 90 days, improvement in NIHSS score and successful reperfusion 
at 27 hours were better in the treatment group versus the control group [64]. There 
was no significant difference in complications between the two groups [64].
The EXTEND IA study aimed to determine whether patients treated with 
both intravenous tPA and Solitaire Revascularization Device within 4.5 hours of 
symptom onset had better outcome than those who were treated with intravenous 
tPA alone [65]. The results of the study showed that reperfusion at 24 hours was 
better in the experimental group versus the control group (median, 100% vs. 
37%, P < 0.001) [65]. The neurological improvement at 3 days and the functional 
outcome was better in the experimental group versus the control group [65]. With 
regards to adverse consequences such as death and intracerebral hemorrhage the 
results were similar between the two groups [65].
Subsequently, a meta-analysis published in 2016 looked at the results from the 
above five randomized controlled trials [60]. There were 1287 patients that were 
included in the study and who had an acute proximal anterior circulation stroke 
[60]. Prior to randomization to the two groups patients received intravenous tPA if 
they met the inclusion criteria [60]. The major results of this meta-analysis were: 
1) endovascular thrombectomy led to reduced disability at 90 days, 2) the risk of 
intracerebral hemorrhage and symptomatic hemorrhage did not differ between the 
groups and 3) the mortality rate was similar between groups [60].
In 2018, two major randomized controlled studies the DAWN and the DEFUSE 3 
were published [66, 67]. The data collected from these studies showed that mechan-
ical thrombectomy can be extended to 24 hours from onset of stroke symptoms [66, 
67]. The DAWN study randomized patients to receive either intravenous tPA alone 
(control group) or thrombectomy plus intravenous tPA (experimental group) [66]. 
The patients had an intracranial internal carotid artery or proximal middle cerebral 
artery occlusion and were last known well 6–24 hours prior [66]. The patients 
included in the study had disproportionately worse neurological exam in compari-
son to the infarct volume that was observed on imaging [66]. The study showed 
that at 90 days the thrombectomy group had a better mRS score and improved 
functional independence [66]. Adverse effects such as intracerebral hemorrhage 
and death were similar between the two groups [66].
The DEFUSE 3 study was a multicenter, randomized, open-label trial, in which 
the control group received intravenous tPA and the experimental group received 
endovascular therapy plus intravenous tPA [67]. Patients who were included in the 
study had onset of symptoms 6–16 hours prior to presentation, were found to have 
proximal middle cerebral artery or internal carotid artery occlusion with initial 
infarct size less than 70 ml and a ratio of the volume of ischemic tissue on perfu-
sion imaging to infarct volume of 1.8 [67]. The study showed that patients who 
underwent mechanical thrombectomy had an increase chance of being functionally 
independent (45% vs. 17%, P < 0.001) and the 90-day mortality rate was 14% in the 
experimental group versus 26% in the control group [67]. Symptomatic intracere-
bral hemorrhage and adverse effects were similar between the groups [67].
It is worth mentioning that acute ischemic stroke can be managed by artery stent-
ing. The Stent-Assisted Recanalization in Acute Ischemic Stroke (SARIS) trial was a 
prospective trial the goal of which was to determine whether cerebral arterial stenting 
would be beneficial in the management of acute ischemic stroke [68]. In a series of 
twenty patients the mRS score of 3 was achieved in 60% and that of 1 was achieved in 
45% [68]. Symptomatic intracerebral hemorrhage was present in 5% of the patients 
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and asymptomatic intracerebral hemorrhage was present in 10% [68]. There is, 
however, no consensus on whether the benefits of arterial stenting in acute stroke 
outweigh the risks primarily due to the lack of randomized controlled trials [69].
6.  Decompressive hemicraniectomy for malignant middle cerebral 
artery territory infarct
Patients who suffer from middle cerebral artery infarction can have a mortal-
ity rate secondary to elevated intracranial pressure. Neurosurgeons often perform 
decompressive craniectomies when such situations arise. Multiple studies were 
conducted over the years to determine the efficacy of this practice. There were three 
randomized controlled landmark studies and a meta-analysis of these studies that 
aimed to address this issue.
The first trial was the “Decompressive Surgery for the Treatment of Malignant 
Infarction of the Middle Cerebral Artery (DESTINY)” that was published in 2007 
[70]. The second trial was the “Sequential-Design, Multicenter, Randomized, 
Controlled Trial of Early Decompressive Craniectomy in Malignant Middle 
Cerebral Artery Infarction (DECIMAL Trial)” that was published in 2007 [71]. The 
third trial was the “Hemicraniectomy after middle cerebral artery infarction with 
life-threatening Edema trial (HAMLET)” published in 2009 [72].
In 2007 a meta-analysis of the above three randomized controlled studies was 
conducted while the above studies were ongoing [73]. The aim of the study was to 
determine whether performing decompressive hemicraniectomy in patients who 
had suffered malignant middle cerebral artery territory infarct had good long-term 
outcomes [73]. The study showed that more patients in the hemicraniectomy group 
had an mRS of less than equal to 4 in comparison to the control group [73]. The 
study also showed that survival rate in the hemicraniectomy group was higher than 
in the control group [73]. This meta-analysis favored decompressive hemicraniec-
tomy in patients with malignant middle cerebral artery infarction who underwent 
surgery within 48 hours of stroke onset in order to reduce mortality and improve 
mRS score in survivors [73].
7. Conclusion
Stroke is a medical entity that was known in ancient Greece as apoplexy. 
Hippocrates was the first to describe a patient with stroke like symptoms followed 
by Areteus and Galen. Ischemic stroke was once a disease process of which we had a 
scarce understanding. Efficient treatments were, however, made possible with more 
insight into the anatomical and pathophysiological changes that are associated with 
ischemic stroke. These developments were attributed to Wepfer, Virchow, Murphy, 
Cooley and others. The advancement in technology, such as the development of 
cerebral angiography, CTA and CTP, were also crucial in the advancements made in 
treating ischemic stroke.
Neurosurgeons are able to perform a wide range of procedures to manage 
ischemic stroke and thus their role in this disease remains pivotal. For prevention of 
stroke, CEAs are performed; for reperfusion of salvageable brain tissue, mechanical 
thrombectomies improve outcomes; and for management of brain herniation hemi-
craniectomies are carried out. Additionally, endovascular mechanical thrombec-
tomies have undoubtedly revolutionized the way ischemic stroke is managed. But, 
more progress remains to be made, with several previous and on-going randomized 
controlled studies attempting to find the gold standard for treating ischemic stroke.
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